StreetInsider.com News Articles

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Intellia Therapeutics Inc. (NASDAQ: NTLA) will present data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran in hereditary angioedema at the European Academy of Allergy & Clinical Immunology Annual Congress 2026, according to a company statement.

The late-breaking oral presentation is scheduled for June 13, 2026, from 8:45 to 9:45 a.m. TRT in Istanbul, Turkey. Dr. Danny Cohn from Amsterdam University Medical Center will present the findings during the immune deficiencies and autoimmunity session.

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia to present Phase 3 HAELO data at EAACI 2026 congress

Mon, 01 Jun 2026 07:30:22 -0400

Lonvoguran ziclumeran, formerly known as NTLA-2002, is a CRISPR gene editing therapy designed to treat hereditary angioedema by inactivating the kallikrein B1 gene with a

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026